+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pacira BioSciences Inc (PCRX) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 56 Pages
  • April 2022
  • GlobalData
  • ID: 4315244
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Pacira BioSciences Inc (PCRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better

The profile contains critical company information including:


  • Business description: A detailed description of the company’s operations and business divisions
  • Corporate strategy: Analyst’s summarization of the company’s business strategy
  • SWOT Analysis: A detailed analysis of the company’s strengths, weakness, opportunities and threats
  • Company history: Progression of key events associated with the company
  • Major products and services: A list of major products, services and brands of the company
  • Key competitors: A list of key competitors to the company
  • Key employees: A list of the key executives of the company
  • Executive biographies: A brief summary of the executives’ employment history
  • Key operational heads: A list of personnel heading key departments/functions
  • Important locations and subsidiaries: A list and contact details of key locations and subsidiaries of the company
  • Detailed financial ratios for the past five years: The latest financial ratios derived from the annual financial statements published by the company with 5 years history
  • Interim ratios for the last five interim periods: The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history

Highlights


Pacira BioSciences Inc (Pacira), formerly Pacira Pharmaceuticals Inc, provides non-opioid pain management and regenerative health solutions. The company develops drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic administered at the time of surgery to control pain and eliminate the use of opioids for acute postsurgical pain. Its other products include iovera, a non-opioid treatment intended to block pain, and relieve pain and symptoms related to osteoarthritis of the knee; among others. Its products are essentially used by hospitals, doctors and ambulatory surgery centers. The company sells products through co-promotion agreements and supply agreements with other pharmaceutical companies. The company has operations in the US and the UK. Pacira is headquartered in Tampa, Florida, the US.

Pacira BioSciences Inc Key Recent Developments


Feb 24, 2022: Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
Feb 15, 2022: Pacira BioSciences reports preliminary net product sales for EXPAREL and iovera° of $37.3 million for January 2022
Dec 07, 2021: Pacira BioSciences reports preliminary net product sales for EXPAREL and iovera of $48.0 million for November 2021
Nov 03, 2021: Pacira BioSciences Reports Third Quarter 2021 Financial Results
Oct 12, 2021: Pacira to acquire Flexion Therapeutics to boost non-opioid pain portfolio

Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios

Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Pacira BioSciences Inc - Key Facts
  • Pacira BioSciences Inc - Key Employees
  • Pacira BioSciences Inc - Key Employee Biographies
  • Pacira BioSciences Inc - Major Products and Services
  • Pacira BioSciences Inc - History
  • Pacira BioSciences Inc - Company Statement
  • Pacira BioSciences Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Section 2 - Company Analysis
  • Company Overview
  • Pacira BioSciences Inc - Business Description
  • Product Category: Bupivacaine liposome injectable suspension
  • Overview
  • Performance
  • Product Category: Collaborative Licensing and Milestone Revenue
  • Performance
  • Product Category: Exparel
  • Overview
  • Performance
  • Product Category: iovera
  • Overview
  • Performance
  • Product Category: Royalty Revenue
  • Performance
  • Product Category: Zilretta
  • Overview
  • Performance
  • R&D Overview
  • Pacira BioSciences Inc - Corporate Strategy
  • Pacira BioSciences Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Pacira BioSciences Inc - Strengths
  • Pacira BioSciences Inc - Weaknesses
  • Pacira BioSciences Inc - Opportunities
  • Pacira BioSciences Inc - Threats
  • Pacira BioSciences Inc - Key Competitors

Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Pacira BioSciences Inc, Recent Deals Summary

Section 5 - Company’s Recent Developments
  • Feb 24, 2022: Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
  • Feb 15, 2022: Pacira BioSciences reports preliminary net product sales for EXPAREL and iovera° of $37.3 million for January 2022
  • Dec 07, 2021: Pacira BioSciences reports preliminary net product sales for EXPAREL and iovera of $48.0 million for November 2021
  • Nov 03, 2021: Pacira BioSciences Reports Third Quarter 2021 Financial Results
  • Oct 08, 2021: Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL
  • Sep 15, 2021: Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021
  • Aug 10, 2021: Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021
  • Jul 20, 2021: Pacira to Report Second Quarter 2021 Financial Results on Tuesday August 3, 2021
  • Jul 13, 2021: Pacira BioSciences reports record revenue of $135.6 million for the second quarter of 2021
  • Jun 08, 2021: Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021

Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Pacira BioSciences Inc, Key Facts
  • Pacira BioSciences Inc, Key Employees
  • Pacira BioSciences Inc, Key Employee Biographies
  • Pacira BioSciences Inc, Major Products and Services
  • Pacira BioSciences Inc, History
  • Pacira BioSciences Inc, Other Locations
  • Pacira BioSciences Inc, Subsidiaries
  • Pacira BioSciences Inc, Key Competitors
  • Pacira BioSciences Inc, Ratios based on current share price
  • Pacira BioSciences Inc, Annual Ratios
  • Pacira BioSciences Inc, Interim Ratios
  • Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Pacira BioSciences Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios

List of Figures
  • Pacira BioSciences Inc, Performance Chart (2017 - 2021)
  • Pacira BioSciences Inc, Ratio Charts
  • Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Pacira BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • DURECT Corp
  • Akorn Inc
  • AcelRx Pharmaceuticals Inc
  • Scilex Pharmaceuticals Inc
  • Napp Pharmaceuticals Ltd
  • Roche Holding, Ltd.